免疫缺陷患者中高度变异的2型疫苗衍生脊髓灰质炎病毒的中和能力
研究检测了采用OPV与灭活脊灰疫苗联合免疫方案人群的血清,对一组免疫缺陷相关疫苗衍生脊灰病毒(iVDPV)的中和能力。结果显示,P1衣壳蛋白氨基酸替换增加导致血清中和能力下降。研究强调在OPV使用地区维持高疫苗覆盖率并对已知免疫缺陷者进行主动监测的重要性。
要点
- P1衣壳蛋白氨基酸替换增加导致血清对iVDPV的中和能力下降。
- 采用OPV与灭活脊灰疫苗联合免疫方案人群的血清对iVDPV中和能力随抗原位点替换程度而异。
- 研究强调OPV使用地区维持高疫苗覆盖率及对免疫缺陷者主动监测的重要性。
核心结论
- P1衣壳蛋白氨基酸替换增加导致血清对iVDPV的中和能力下降,强调在OPV使用地区维持高疫苗覆盖率并主动监测免疫缺陷者。
研究设计与样本
- 检测采用OPV与灭活脊灰疫苗联合免疫方案人群的血清,对一组iVDPV进行中和能力测试。
主要发现
- P1衣壳蛋白氨基酸替换增加导致血清中和能力下降。
临床怎么用
- 作者强调在OPV使用地区维持高疫苗覆盖率并对已知免疫缺陷者进行主动监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of the oral poliovirus vaccine (OPV) in developing countries has reduced the incidence of poliomyelitis by >99% since 1988 and is the primary tool for global polio eradication. Spontaneous reversions of the vaccine virus to a neurovirulent form can impede this effort. In persons with primary B-cell immunodeficiencies, exposure to OPV can result in chronic infection, mutation, and excretion of immunodeficiency-associated vaccine-derived polioviruses, (iVDPVs). These iVDPVs may have the potential for transmission in a susceptible population and cause paralysis. The extent to which sera from OPV recipients are able to neutralize iVDPVs with varying degrees of antigenic site substitutions is investigated here. We tested sera from a population immunized with a combination vaccine schedule (both OPV and inactivated polio vaccine) against a panel of iVDPVs and found that increases in amino acid substitution in the P1 capsid protein resulted in a decrease in the neutralizing capacity of the sera. This study underscores the importance of maintaining high vaccine coverage in areas of OPV use as well as active surveillance of those known to be immunocompromised.
引用
- McDonald SL, Weldon WC, Wei L, et al. Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients. Vaccine. 2020. PMID: 32089462. doi:10.1016/j.vaccine.2020.02.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。